Age-related Macular Degeneration (AMD) Drugs Market Size, Share, Forecast Report 2026 to 2035
What is Age-related Macular Degeneration (AMD) Drugs Market Size?
Global Age-related Macular Degeneration (AMD) Drugs Market Size is valued at USD 11.21 Bn in 2025 and is predicted to reach USD 27.96 Bn by the year 2035 at an 9.7% CAGR during the forecast period for 2026 to 2035.
Age-related Macular Degeneration (AMD) Drugs Market Size, Share & Trends Analysis Distribution by Products (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre, Other Products), Molecules (Ranibizumab, Aflibercept, Faricimab, Pegcetoplan, Other Molecules), Type of AMD (Wet AMD, Dry AMD), Approval type (Biologic, Biosimilar) End User and Segment Forecasts, 2026 to 2035.
-Drugs-Market-Infographics.webp "Age-related Macular Degeneration (AMD) Drugs Market Infographics")
Age-related Macular Degeneration (AMD) Drugs Market Key Takeaways:
|
Age-related macular degeneration is a degenerative eye disease commonly occurring after the age of 50, leading to vision loss in the inner area of the visual field. There are two types: dry AMD - degeneration of vision due to gradual thinning of the macula; wet AMD - rapid degeneration through unhealthy growth under the retina. Treatment for AMD is primarily aimed at the wet form with anti-vascular endothelial growth factor (anti-VEGF) therapies, including Eylea (aflibercept), Lucentis (ranibizumab), and new Vabysmo (faricimab). In 2023, the FDA authorized Syfovre, the inaugural medicine for treating dry age-related macular degeneration (AMD). Syfovre is the first treatment to receive FDA approval, having shown a reduction of around 20% in the progression of blind spots associated with advanced dry macular degeneration over a two-year period.
Major drivers for the AMD drug market include an increasing emphasis on research and development. New formulations and delivery systems are developed to minimize side effects, enhance treatment effectiveness, and enhance compliance by either extending dosing intervals or offering alternative delivery mechanisms. Additionally, novel therapies for wet and dry AMD will propel future market growth by bridging unmet medical needs within the studied patient population.
Competitive Landscape
Some of the Key Players in Age-related Macular Degeneration (AMD) Drugs Market:
- Regeneron Pharmaceuticals Inc. (US)
- Bayer AG (Germany)
- Hoffmann-La Roche AG (Switzerland)
- Novartis AG (Switzerland)
- Apellis Pharmaceuticals, Inc. (US)
- Coherus BioSciences, Inc. (US)
- Astellas Pharma Inc. (Japan)
- Biogen (US)
- STADA Arzneimittel AG (Germany)
- Formycon AG (Germany)
- (India)
- Outlook Therapeutics, Inc. (US)
- Intas Pharmaceuticals Ltd. (India)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Chengdu Kanghong Biotech Company (China)
- Sandoz Group AG (Switzerland)
- Stealth BioTherapeutics Inc. (US)
- Ocular Therapeutix, Inc. (US)
- Opthea Limited, Inc. (Australia)
- Kodiak Sciences Inc. (US)
- Innovent Biologics, Inc. (China)
- Bio-Thera Solution Inc. (China)
- Alvotech (Iceland)
- Alteogen Inc. (South Korea)
- Shanghai Henlius Biotech, Inc. (China)
- Amgen Inc. (US)
- Ocumension Therapeutics. (China)
- Adverum Biotechnologies, Inc. (US)
Market Segmentation:
The age-related Macular Degeneration (AMD) Drugs market is segmented by products, molecules, type of AMD, approval type, end user. By products the market is segmented into lucentis, eylea & eylea HD, vabysmo, syfovre, other products. By molecules market is categorized into ranibizumab, aflibercept, faricimab, pegcetoplan, other molecules. By type of AMD market is categorized into wet AMD, dry AMD. By approval type market is segmented into biologic, biosimilar. By end user the market is categorized into hospitals, specialty centers, and long-term care facilities.
Eylea and Eylea HD Segment is Expected to Drive the Age-related Macular Degeneration (AMD) Drugs Market
The Eylea and Eylea HD segment is a significant driver in the Age-related Macular Degeneration drugs market through its established efficacy, broad acceptance, and continuous innovations that enhance treatment protocols. Through its higher dose (8 mg as opposed to 2 mg), Eylea HD has shown promise in the elongation of treatment intervals, thus making it less burdensome for patients and, therefore, presumably enhancing compliance. Long-term dosing for this kind of drug is part of a strategic approach against competitors like Roche's Vabysmo, which has the benefit of doing once a month. These developments and research into new formulations and delivery systems position Regeneron at the competitive edge in AMD drugs. All these factors ensure Eylea and Eylea HD remain the frontier AMD treatments, driving up market growth and leading to future choices in therapeutics.
Dry AMD is Growing at the Highest Rate in the Age-related Macular Degeneration (AMD) Drugs Market.
The Dry AMD segment is expected to grow considerably in the market for drugs targeted at treating age-related macular degeneration (AMD). Recent FDA approvals, with a strong pipeline of new therapies and growing prevalence, will propel the Dry AMD segment forward. Approvals over 2023 for such key therapies as Pegcetacoplan in Syfovre and Avacincaptad Pegol in IZERVAY indicated the need for effective treatments for dry AMD and infused confidence in the market, attracting still further investment. But finally, promising pipelines in terms of peptide derivatives and gene therapies from companies like Alkeus Pharmaceuticals and Belite Bio bode well for future progress. Dry AMD accounts for almost 90% of all cases of AMD and is increasing with global aging; hence, it is an important segment and encourages pharmaceutical companies to act fast, accelerate new treatments, and ensure big returns.
Regionally, North America Led the Age-related Macular Degeneration (AMD) Drugs Market.
North America leads in this market, largely due to a high incidence rate of AMD, high pharmaceutical R&D capabilities, and multiple available therapies. Regionally, the market is experiencing increased unmet needs, with nearly 200,000 new cases diagnosed each year. Similarly, strong R&D investments are made in North America, and as a result, some major pharmaceutical research-oriented institutes are also present there; for example, the recent approval of biosimilar Enzeevu for treating wet AMD. Apart from this, numerous treatment options are available, including Eylea, Lucentis, Vabysmo, and Syfovre, which places all patients at a developed level of care.
-Drugs-Market-Regional-Analysis.webp "Age-related Macular Degeneration (AMD) Drugs Market Regional Analysis")
Age-related Macular Degeneration (AMD) Drugs Market Report Scope :
| Report Attribute | Specifications |
| Market Size Value In 2025 | USD 11.21 Bn |
| Revenue Forecast In 2035 | USD 27.96 Bn |
| Growth Rate CAGR | CAGR of 9.7 % from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Products, Molecules, Type of AMD, Approval type, End User and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; Southeast Asia |
| Competitive Landscape | Regeneron Pharmaceuticals Inc. (US), Bayer AG (Germany), F. Hoffmann-La Roche AG (Switzerland), Novartis AG (Switzerland), Apellis Pharmaceuticals, Inc. (US), Coherus BioSciences, Inc. (US), Astellas Pharma Inc. (Japan), Biogen (US), STADA Arzneimittel AG (Germany), Formycon AG (Germany), Biocon. (India), Outlook Therapeutics, Inc. (US), Intas Pharmaceuticals Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Chengdu Kanghong Biotech Company (China), Sandoz Group AG (Switzerland), Stealth BioTherapeutics Inc. (US), Ocular Therapeutix, Inc. (US), Opthea Limited, Inc. (Australia), Kodiak Sciences Inc. (US), Innovent Biologics, Inc. (China), Bio-Thera Solution Inc. (China), Alvotech (Iceland), Alteogen Inc. (South Korea), Shanghai Henlius Biotech, Inc. (China), Amgen Inc. (US), Ocumension Therapeutics. (China) and Adverum Biotechnologies, Inc. (US) |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of Age-related Macular Degeneration (AMD) Drugs Market :
Age-related Macular Degeneration (AMD) Drugs Market by Products -
- Lucentis
- Eylea & Eylea HD
- Vabysmo
- Syfovre
- Other Products
-Drugs-Market-Segmentation-Analysis.webp "Age-related Macular Degeneration (AMD) Drugs Market Segmentation Analysis")
Age-related Macular Degeneration (AMD) Drugs Market by Molecules -
- Ranibizumab
- Aflibercept
- Faricimab
- Pegcetoplan
- Other Molecules
Age-related Macular Degeneration (AMD) Drugs Market by Type of AMD -
- Wet AMD
- Dry AMD
Age-related Macular Degeneration (AMD) Drugs Market by Type of Approval type -
- Biologic
- Biosimilar
Age-related Macular Degeneration (AMD) Drugs Market by End User -
- Hospitals
- Specialty Centers
- Long-Term Care Facilities
Age-related Macular Degeneration (AMD) Drugs Market by Region-
- North America-
- The US
- Canada
- Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
- Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Age-related Macular Degeneration (AMD) Drugs Market Size is valued at USD 11.21 Bn in 2025 and is predicted to reach USD 27.96 Bn by the year 2035.
Age-related Macular Degeneration (AMD) Drugs Market is expected to grow at an 9.7% CAGR during the forecast period for 2026-2035.
Regeneron Pharmaceuticals Inc. (US), Bayer AG (Germany), F. Hoffmann-La Roche AG (Switzerland), Novartis AG (Switzerland), Apellis Pharmaceuticals, In
The Age-related Macular Degeneration (AMD) Drugs Market includes five segments Products, Molecules, Type of AMD, Approval type, and End-User, lucentis, eylea & eylea HD, vabysmo, syfovre, other products.
North American region is leading the Age-related Macular Degeneration (AMD) Drugs Market.